Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Sep 26, 2017
DURHAM, N.C., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced the appointment of Richard Morrison, PhD,...
Sep 19, 2017
DURHAM, N.C., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, will hold a conference call to discuss an upda...
Sep 12, 2017
DURHAM, N.C., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today reported on an update on the interim analysis of da...
Sep 6, 2017
DURHAM, N.C., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today reported that for the first time a patient in the o...
Aug 21, 2017
DURHAM, N.C., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that an interim analysis of data from the ...
Aug 9, 2017
- Announced Continuation of the ADAPT Trial following Meeting with the FDA - - Raised Gross Proceeds of $6.0 million in Secured Convertible Note Financing - - Reported Positive Immunogenicity Data in AGS-004 Program for the Treatment of HIV - ...
Jul 26, 2017
DURHAM, N.C., July 26, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced immunogenicity data from a stud...
Jun 22, 2017
DURHAM, N.C., June 22, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced the closing o...
Jun 16, 2017
DURHAM, N.C., June 16, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced that it entered ...
May 10, 2017
DURHAM, N.C., May 10, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today provided an update on the ADAPT trial, a r...
Apr 18, 2017
DURHAM, N.C., April 18, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today reported interim results from its random...
Feb 22, 2017
-Company to host conference call today, February 22, 2017 at 8:30am EST- DURHAM, N.C., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the A...
Feb 13, 2017
DURHAM, N.C., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that the comp...
Feb 6, 2017
DURHAM, N.C., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that the company...
Jan 19, 2017
DURHAM, N.C., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, announced today the completion ...
Page:
...
Next Last
 
= add release to Briefcase

Stock Quote

NASDAQ: ARGS
0.17
- 0.00 (-2.53%)

Day High:
0.17

Day Low:
0.16

Volume:
2,767,077

3:59 PM ET on Oct 17, 2017
Delayed at least 20 minutes.

Tweets